SCHEMBL9804292

SCHEMBL9804292

C[Si](C)(C)n1ccc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 4/20 0.45
CCND1 P24385 4/20 0.45
NOTUM Q6P988 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
PBRM1 Q86U86 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A2 P23975 4/20 0.41
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
MAPK1 P28482 1/20 0.39
BIRC5 O15392 1/20 0.38
CA12 O43570 1/20 0.38
BRD4 O60885 1/20 0.38
BRPF1 P55201 1/20 0.38
CA9 Q16790 1/20 0.38
KAT2B Q92831 1/20 0.38
BRD9 Q9H8M2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479213 1.00 CDK4 (0.45) CDK4CCND1NOTUMSMN1; SMN2PBRM1
SCHEMBL29479212 1.00 CDK4 (0.45) CDK4CCND1NOTUMSMN1; SMN2PBRM1
SCHEMBL3334605 0.79 CDK4 (0.39) CDK4CCND1NOTUMSMN1; SMN2PBRM1
SCHEMBL29236 0.77 SLC6A2 (0.41) CDK4CCND1NOTUMSMN1; SMN2PBRM1
SCHEMBL11787645 0.76 CDK4 (0.54) CDK4CCND1NOTUML3MBTL1HTR2A
SCHEMBL29479215 0.72 HTR2A (0.45) CDK4CCND1HTR2AHTR2CALDH1A1
SCHEMBL29812 0.69 CDK4 (0.56) CDK4CCND1NOTUMHTR2AHTR2C
SCHEMBL29384135 0.69 CDK4 (0.56) CDK4CCND1NOTUMHTR2AHTR2C
SCHEMBL598296 0.68 SLC6A2 (0.47) CDK4CCND1NOTUMSLC6A2
SCHEMBL321199 0.68 CDK4 (0.45) CDK4CCND1NOTUMSMN1; SMN2PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106543304-B Method for synthesizing metallocene catalyst 中国科学院上海高等研究院 2020-03-31 CN disclosed
CN-107820494-A Nuclear receptor modulators 艾伯维公司 2018-03-20 CN disclosed
US-7358398-B2 of aromatic groups using transition metal catalysis in compressed carbon dioxide; intermediates ASTRAZENECA UK LIMITED (GB) 2008-04-15 US disclosed
US-20070179315-A1 Methods of amination ASTRAZENECA UK LIMITED (GB) 2007-08-02 US disclosed
EP-0413464-A2 Catalysts IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-02-20 EP disclosed
EP-0413465-A2 Catalysts IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-02-20 EP disclosed
EP-0405786-A2 Catalysts IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-01-02 EP disclosed
US-4981827-A Catalysts IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-01-01 US disclosed
EP-0323082-A2 Catalysts IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179315-A1 Methods of amination C5, CBR3, CCNL2 CDK4 2114/4885CCND1 432/4885NOTUM 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.